IXSBF yields 2000000.00% · MRK yields 2.76%● Live data
📍 IXSBF pulled ahead of the other in Year 1
Combined, IXSBF + MRK cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IXSBF + MRK for your $10,000?
InNexus Biotechnology, Inc., a development stage company, engages in the commercialization of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. Its DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effector functions, and installing new properties into antibodies. The company's products in pipeline include DXL625, a monoclonal antibody in late stage pre-clinical development produced with enhanced binding kinetics and effector functions for the treatment of B cell non-Hodgkins lymphoma (NHL) and DXLr120, a recombinant DXL anti-CD20 antibody being developed for the treatment of B cell NHL cancer; DXL702, a monoclonal antibody being developed for the treatment of metastatic breast cancer; and DXL1218, which targets an antigen designated epidermal growth factor receptor that is over expressed in metastatic colorectal cancer and in squamous cell carcinomas of the head and neck. It has collaboration agreements with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is headquartered in Vancouver, Canada.
Full IXSBF Calculator →Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Full MRK Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.